REFERENCES
1. Oskarsson T, Soderhall S, Arvidson J, et al. Relapsed childhood acute
lymphoblastic leukemia in the Nordic countries: prognostic factors,
treatment and outcome. Haematologica. 2016;101(1):68-76.
2. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with
relapsed acute lymphoblastic leukemia after time-point and
site-of-relapse stratification and intensified short-course multidrug
chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol.2010;28(14):2339-2347.
3. Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab
treatment in pediatric patients with relapsed/refractory B-cell
precursor acute lymphoblastic leukemia. Blood Cancer J.2018;8(9):80.
4. LaBelle JL, Cunningham JM. Stem cell transplant as an
immunomodulatory tool for children with hematologic malignancies.Am Soc Clin Oncol Educ Book.2013:10.1200/EdBook_AM.2013.1233.e1347.
5. Wyatt KD, Bram RJ. Immunotherapy in pediatric B-cell acute
lymphoblastic leukemia. Hum Immunol. 2019;80(6):400-408.
6. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine,
cyclophosphamide and etoposide as single-course re-induction therapy for
children with refractory/multiple relapsed acute lymphoblastic
leukaemia. Br J Haematol. 2009;147(3):371-378.
7. Taraseviciute A, Broglie L, Phelan R, Bhatt NS, Becktell K, Burke MJ.
What is the Role of Hematopoietic Cell Transplantation (HCT) for
Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric
Antigen Receptor T-Cell (CART) Therapy? Journal of pediatric
hematology/oncology. 2019;41(5):337-344.
8. Przespolewski A, Szeles A, Wang ES. Advances in immunotherapy for
acute myeloid leukemia. Future Oncol. 2018;14(10):963-978.
9. Bertaina A, Zecca M, Buldini B, et al. Unrelated donor vs
HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with
acute leukemia. Blood. 2018;132(24):2594-2607.
10. Erbey F, Akcay A, Atay D, Ovali E, Ozturk G. Comparison of outcomes
after HLA-matched unrelated and alphabeta T-cell-depleted haploidentical
hematopoietic stem cell transplantation for children with high-risk
acute leukemia. Pediatr Transplant. 2018;22(4):e13192.
11. Sharma A, Kang G, Sunkara A, et al. Haploidentical Donor
Transplantation Using a Novel Clofarabine-containing Conditioning
Regimen for Very High-risk Hematologic Malignant Neoplasms. J
Pediatr Hematol Oncol. 2018;40(8):e479-e485.
12. Shelikhova L, Ilushina M, Shekhovtsova Z, et al. alphabeta T
Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation
without Antithymocyte Globulin in Children with Chemorefractory Acute
Myelogenous Leukemia. Biol Blood Marrow Transplant.2019;25(5):e179-e182.
13. Eckert C, Henze G, Seeger K, et al. Use of Allogeneic Hematopoietic
Stem-Cell Transplantation Based on Minimal Residual Disease Response
Improves Outcomes for Children With Relapsed Acute Lymphoblastic
Leukemia in the Intermediate-Risk Group. Journal of Clinical
Oncology. 2013;31(21):2736-2742.
14. Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual
Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic
Leukemia: A Meta-analysis. JAMA Oncol. 2017;3(7):e170580.
15. Araki D, Wood BL, Othus M, et al. Allogeneic Hematopoietic Cell
Transplantation for Acute Myeloid Leukemia: Time to Move Toward a
Minimal Residual Disease-Based Definition of Complete Remission? J
Clin Oncol. 2016;34(4):329-336.
16. Pulsipher MA, Langholz B, Wall DA, et al. Risk factors and timing of
relapse after allogeneic transplantation in pediatric ALL: for whom and
when should interventions be tested? Bone Marrow Transplant.2015;50(9):1173-1179.
17. Jeha S, Razzouk B, Rytting M, et al. Phase II study of clofarabine
in pediatric patients with refractory or relapsed acute myeloid
leukemia. J Clin Oncol. 2009;27(26):4392-4397.
18. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine
in pediatric patients with refractory or relapsed acute lymphoblastic
leukemia. J Clin Oncol. 2006;24(12):1917-1923.